Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8965 results

  1. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    Health technology evaluations
    In development

  4. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTG10173 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development

  11. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  12. Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  16 February 2027

    Quality standard
    In development

  13. High linear energy transfer radiation for carbon ion beam therapy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Spirecut's Sono-Instruments to treat carpal tunnel syndrome and trigger finger

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. High resolution anoscopy and laser therapy for intraepithelial neoplasia of the anus in high risk or immunocompromised patients

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation